Aceragen Inc | IDRA - Operating Expenses

Idera Pharmaceuticals reported $9.33M in Operating Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Operating Expenses Change
Abbott ABT:US USD 8.76B 123M
Agenus AGEN:US USD 88.08M 23.66M
Alnylam Pharmaceuticals ALNY:US USD 523.65M 75.28M
Amgen AMGN:US USD 4.61B 695M
Biogen BIIB:US USD 1.84B 650.7M
Biomarin Pharmaceutical BMRN:US USD 562.04M 54.28M
Cytrx CYTR:US USD 1.29M 7.73M
Dynavax Technologies DVAX:US USD 121.36M 15.02M
Eli Lilly And LLY:US USD 5.47B 200.3M
Gilead Sciences GILD:US USD 5.12B 917M
GlaxoSmithKline GSK:LN GBP 5.51B 1.13B
Idera Pharmaceuticals IDRA:US USD 9.33M 3.96M
Merk MRK:US USD 10.32B 624M
Mirati Therapeutics MRTX:US USD 212.66M 20.78M
Nektar Therapeutics NKTR:US USD 74.49M 3.43M
Pfizer PFE:US USD 19.12B 5.9B
Roche Holding ROG:VX 25.06B 4.31B
Sarepta Therapeutics SRPT:US USD 367.84M 119.23M
Seattle Genetics SGEN:US USD 682.15M 20.95M
Ultragenyx Pharmaceutical RARE:US USD 248.98M 66.79M